Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12612000481875
Ethics application status
Approved
Date submitted
26/04/2012
Date registered
2/05/2012
Date last updated
30/07/2012
Type of registration
Prospectively registered

Titles & IDs
Public title
A low residue diet versus clear fluids prior to colonoscopy. The impact on bowel preparation quality and tolerability.
Scientific title
A low residue diet versus clear fluids prior to colonoscopy. The impact on bowel preparation quality and tolerability.
Secondary ID [1] 280393 0
Nil
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Colonoscopy bowel preparation 286373 0
Condition category
Condition code
Oral and Gastrointestinal 286615 286615 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Low residue diet on the day prior to colonoscopy

This commences at breakfast on the day prior to colonoscopy

A low residue diet is one that contains few indigestible components. Foods allowed include such thing as cheese, white bread, pasta and vanilla ice cream among others
Intervention code [1] 284755 0
Other interventions
Comparator / control treatment
Clear fluid diet on the day prior to colonoscopy

This commences on the day prior to colonoscopy after 7am (A light breakfast is allowed before 7 am).

Clear fluids allowed include such fluids as water, lemonade, apple juice and clear soup broth
Control group
Active

Outcomes
Primary outcome [1] 287028 0
Successful bowel preparation (cleanliness) as defined by an overall grading of A or B on the Harefield Bowel Cleansing Scale
Timepoint [1] 287028 0
At the time of colonoscopy
Secondary outcome [1] 297235 0
Bowel preparation (cleanliness) by colonic segment as defined by the Harefield Bowel Cleansing Scale
Timepoint [1] 297235 0
At the time of colonoscopy
Secondary outcome [2] 297236 0
Tolerance, acceptance and compliance with the dietary regimen and bowel preparation regimen as assessed by a questionairre and food diary. The questionnaire contains questions about compliance with the bowel preparation regimen, medication use and some co-morbid conditions. It also contains questions with visual analogue scale responses in order to assess tolerance to the bowel preparation regimen. It has not previously been validated.
Timepoint [2] 297236 0
Questionnaire administered on the day of colonoscopy, prior to the procedure

Food diary completed over the 24 hours prior to the colonoscopy
Secondary outcome [3] 297237 0
Factors other than dietary allocation that affect bowel preparation quality such as a history of constipation, laxative use, opioid use, body mass index, diagnosis of diabetes mellitus
Timepoint [3] 297237 0
As assessed by the questionnaire administered on the day of colonoscopy, prior to the procedure
Secondary outcome [4] 297238 0
Polyp detection rate/adenoma detection ratio
Timepoint [4] 297238 0
At the time of colonoscopy
Secondary outcome [5] 297239 0
Caecal intubation rate
Timepoint [5] 297239 0
At the time of colonoscopy
Secondary outcome [6] 297240 0
Time to complete colonoscopy
Timepoint [6] 297240 0
At the time of colonoscopy
Secondary outcome [7] 297241 0
Bowel preparation (cleanliness) as defined by the Harefield Bowel Cleansing Scale for Morning versus Afternoon procedures
Timepoint [7] 297241 0
At the time of colonoscopy

Eligibility
Key inclusion criteria
participants who are undergoing outpatient colonoscopy for clinically accepted indications
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Conditions generally considered as exclusions to colonoscopy in normal clinical practice. They are suspected bowel perforation, gastric outlet obstruction, toxic megacolon, severe colitis, and pregnancy or lactation.

Significant renal failure (eGFR<30) or significant heart failure (New York Heart Association Class III or IV).

History of phenylketonuria (PKU) or Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency and any person with a known hypersensitivity to a constituent of Movicol (Registered Trademark).

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Persons who require an outpatient colonoscopy will be invited to participate. Participants will be randomly allocated to one of the dietary regimens on a 1:1 basis. This will be done via the opening of a sealed opaque envelope at the time that the colonoscopy is booked to an endosocopy list
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer generated randomisation in permuted blocks
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
30/07/2012
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
250
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 285162 0
Commercial sector/Industry
Name [1] 285162 0
Norgine Pharmaceuticals
Country [1] 285162 0
Australia
Primary sponsor type
Individual
Name
Dr Gregor Brown
Address
Head of Endoscopy
Department of Gastroenterology
The Alfred Hospital
Level 4
55 Commercial Road
Prahran
VIC 3181
Country
Australia
Secondary sponsor category [1] 284029 0
Individual
Name [1] 284029 0
Dr Joshua Butt
Address [1] 284029 0
Endoscopy Fellow
The Department of Gastroenterology
The Alfred Hospital
Level 4
55 Commercial Road
Prahran
VIC 3181
Country [1] 284029 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 287175 0
Alfred Health Human Ethics Committee
Ethics committee address [1] 287175 0
Ethics committee country [1] 287175 0
Australia
Date submitted for ethics approval [1] 287175 0
23/02/2012
Approval date [1] 287175 0
30/04/2012
Ethics approval number [1] 287175 0
45-12

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 34112 0
Address 34112 0
Country 34112 0
Phone 34112 0
Fax 34112 0
Email 34112 0
Contact person for public queries
Name 17359 0
Dr Joshua Butt
Address 17359 0
Endoscopy Fellow
Department of Gastroenterology
The Alfred Hospital
55 Commercial Rd
Prahran
VIC 3181
Country 17359 0
Australia
Phone 17359 0
+61 3 92762000
Fax 17359 0
Email 17359 0
j.butt@alfred.org.au
Contact person for scientific queries
Name 8287 0
Dr Gregor Brown
Address 8287 0
Head of Endoscopy
Department of Gastroenterology
The Alfred Hospital
55 Commercial Rd
Prahran
VIC 3181
Country 8287 0
Australia
Phone 8287 0
+61 3 90763375
Fax 8287 0
Email 8287 0
g.brown@alfred.org.au

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.